Home » Stocks » BCDA

BioCardia, Inc. (BCDA)

Stock Price: $3.32 USD 0.02 (0.61%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 55.76M
Revenue (ttm) 145,000
Net Income (ttm) -15.00M
Shares Out 10.12M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.32
Previous Close $3.30
Change ($) 0.02
Change (%) 0.61%
Day's Open 3.30
Day's Range 3.27 - 3.39
Day's Volume 67,212
52-Week Range 1.91 - 8.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 14.29% and 31.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

11 hours ago - Zacks Investment Research

SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today ...

16 hours ago - GlobeNewsWire

Second Biotherapeutic Partnership of 2021 Second Biotherapeutic Partnership of 2021

2 weeks ago - GlobeNewsWire

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 48.39% and -58.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative therapies, to...

1 month ago - GlobeNewsWire

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that C...

1 month ago - GlobeNewsWire

SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced c...

2 months ago - GlobeNewsWire

SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an ...

3 months ago - GlobeNewsWire

SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Krisztin...

4 months ago - GlobeNewsWire

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune...

Other stocks mentioned: ALT, INCY
4 months ago - Benzinga

Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Stru...

4 months ago - GlobeNewsWire

SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the...

4 months ago - GlobeNewsWire

Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over the past tw...

4 months ago - Market Watch

SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purcha...

4 months ago - GlobeNewsWire

SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchas...

4 months ago - GlobeNewsWire

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchas...

4 months ago - GlobeNewsWire

BioCardia (BCDA) news for Monday includes an announcement concerning interim clinical trial results boosting BCDA stock higher. The post BioCardia News: Why BCDA Stock Is Soaring Today appeared first on...

4 months ago - InvestorPlace

BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Failure Trial.

Other stocks mentioned: HCA, PACB
4 months ago - Benzinga

SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company's proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated ...

5 months ago - GlobeNewsWire

SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and busine...

6 months ago - GlobeNewsWire

Paper P ublished in International Journal of Cardiology D emonstrates S afety and T olerability W hile S howing F unctional I mprovement at S ix M onths

6 months ago - GlobeNewsWire

Technology May Enable Same-Day Outpatient Cell Therapy Procedures Technology May Enable Same-Day Outpatient Cell Therapy Procedures

7 months ago - GlobeNewsWire

SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announce...

8 months ago - GlobeNewsWire

SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported ...

9 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announce...

9 months ago - GlobeNewsWire

First Site Initiation Visit in Trial Completed and Executive Steering Committee Named First Site Initiation Visit in Trial Completed and Executive Steering Committee Named

10 months ago - GlobeNewsWire

SAN CARLOS, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...

10 months ago - GlobeNewsWire

SAN CARLOS, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapie...

10 months ago - GlobeNewsWire

SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported...

11 months ago - GlobeNewsWire

SAN CARLOS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported...

1 year ago - GlobeNewsWire

SAN CARLOS, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced ...

1 year ago - GlobeNewsWire

SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced ...

1 year ago - GlobeNewsWire

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addit... [Read more...]

Industry
Biotechnology
CEO
Peter Altman
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
BCDA
Full Company Profile

Financial Performance

In 2020, BioCardia's revenue was $145,000, a decrease of -79.58% compared to the previous year's $710,000. Losses were -$15.00 million, 2.01% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BioCardia stock is "Buy" and the 12-month stock price forecast is 12.50.

Price Target
$12.50
Analyst Consensus: Buy